KBP-7018 is a potent, selective tyrosine kinase inhibitor with effects on three fibrotic kinases c-KIT, RET, and PDGFR (IC50 values are 10nM, 7.6 nM and 25nM respectively).
GSK-2793660 is a cathepsin C inhibitor that may be useful in the treatment of cystic fibrosis, noncystic fibrosis bronchiectasis, ANCA-associated vasculitis and bronchiectasis.